4 2 1 a r t i c l e s Oral mucositis, marked by severe oral ulcerations, is a common adverse effect of large-dose radiation used before bone-marrow transplantation or craniofacial radiotherapy for cancer 1,2 . Severe oral mucositis can lead to the need for feeding tubes, management of severe pain and a premature halt to radiotherapy 1 . Excessive inflammation and epithelial ablation are key features of oral mucositis 3,4 . Palifermin, a truncated human keratinocyte growth factor (KGF) recombinant protein, is approved for preventing oral mucositis in patients receiving bone-marrow transplant 1 . Two palifermin clinical trials in patients with head and neck cancer showed that the drug reduced the incidence of severe oral mucositis from 67% and 69% to 51% and 54%, respectively 5,6 . Other oral mucositis drugs in clinical trials or preclinical studies include growth factors 7-9 , agents for radioprotection 10-12 , anti-inflammatory agents and immune modulators [13] [14] [15] [16] .
a r t i c l e s in wild-type mice but showed resistance to radiation-induced oral mucositis ( Fig. 1a,b) . Histological analyses revealed that wild-type mice developed oral mucositis ( Fig. 1a ) similar to that in humans ( Fig. 1c) . Oral epithelia in K5.Smad7 mice typically showed radiation dose-dependent damage: we observed thinning epithelium and flattened tongue papillae after 8 Gy × 3 radiation and more damaged (hypotrophic or hypertrophic) epithelial cells after 18 Gy and 22 Gy radiation ( Fig. 1a) . Consistent with more leukocyte infiltration in human oral mucositis lesions than in normal human oral mucosa ( Fig. 1c) , lesions in wild-type mice harbored numerous infiltrated leukocytes ( Fig. 1d,e ) consisting of neutrophils, macrophages and lymphocytes ( Supplementary Fig. 1d ); there were substantially fewer infiltrated leukocytes in the oral mucosa of K5.Smad7 mice (Fig. 1d,e and Supplementary Fig. 1d) .
Because it is difficult to capture human oral mucositis pathology at the acute phase, we used a mouse model to assess proliferation and apoptosis when ulcers have just formed. Similarly to previous reports 7, 12 , proliferative cells were sparse in the oral epithelium of irradiated wild-type mice but were present at higher numbers in the oral epithelium of irradiated K5.Smad7 mice (Fig. 1d,f) . Conversely, the number of apoptotic cells was significantly lower in the oral mucosa of irradiated K5.Smad7 mice as compared to irradiated wildtype mice (Fig. 1d,g) .
The number of cells in the oral mucosa with positive staining for the nuclear NF-κB p50 subunit was significantly higher in irradiated wild-type mice with oral mucositis compared to nonirradiated controls ( Fig. 2a,b) . The immunostaining intensity of TGF-β1 protein, which is an immune suppressant in internal organs 21, 22 but is proinflammatory in oral mucosa 23 , together with the number of cells positive for the TGF-β1 activated signaling mediator phosphorylated Smad2 (pSmad2) were also higher in the oral mucosa of wild-type irradiated mice compared to nonirradiated control mice ( Fig. 2a,b) . We also detected similar changes in human oral mucositis lesions ( Fig. 2a,b) . The oral epithelia of irradiated K5.Smad7 mice had significantly lower numbers of cells positive for nuclear NF-κB subunit p50 and pSmad2 compared to irradiated wild-type mice, even though they still had abundant TGF-β1 protein ( Fig. 2a,b) . TGF-β1 mRNA levels in the oral mucosa of irradiated wild-type mice were significantly increased on day 9 and day 10 after irradiation as compared to on day 0 ( Fig. 2c) . TGF-β1 mRNA levels in oral mucosa of K5.Smad7 mice were similar to those from wild-type mice without irradiation or at earlier time points after irradiation but returned to their initial levels by day 10 (Fig. 2c) . These data suggest that TGF-β1 transcription is not inhibited by Smad7, but its more rapid decline in the mucosa of K5.Smad7 mice could be a consequence of accelerated healing. Immunostaining of pSmad1, npg a r t i c l e s nature medicine VOLUME 19 | NUMBER 4 | ApRiL 2013 pSmad5 or pSmad8, markers for activated bone morphogenic protein signaling 24 , was not affected by Smad7 before or after irradiation ( Supplementary Fig. 1e ). This result is consistent with the ability of Smad7 to preferentially inhibit TGF-β signaling.
Rac1 contributed to Smad7-mediated keratinocyte migration
To determine whether Smad7 contributes to healing in human oral keratinocytes, we knocked down Smad7 in spontaneously immortalized human oral keratinocytes (NO+K-SI cells) 25 Supplementary Fig. 3a and images in Supplementary Fig. 3d ). n = 3 per group. Data are presented as the mean ± s.d. siRac1-1 and siRac1-2 are two siRNAs specific for Rac1. *P < 0.05, **P < 0.01, ***P < 0.001, NS, no significance determined by two-tailed Student's t test. CtBP1 binding to Rac1 promoter (fold) knockdown blunted keratinocyte migration after wounding ( Fig. 2d and Supplementary Fig. 2a ). Conversely, knocking down TGF-β1 accelerated keratinocyte migration ( Supplementary Fig. 2b-d) , consistent with accelerated wound healing in mice null for TGF-β1 or Smad3 (refs. 26, 27) . To search for molecular mechanisms associated with Smad7-mediated keratinocyte migration, we examined RAS-related C3 botulinum substrate 1 (Rac1), a protein that is indispensable for oral wound healing 25 . The amount of Rac1 protein was reduced after Smad7 knockdown ( Fig. 2e) . We expected that TGF-β1 overexpression in oral mucositis would activate Rac1 through a Smadindependent mechanism 28 . However, although the amount of total Rac1 protein was twofold higher after irradiation, the amount of activated Rac1 protein did not change considerably in wild-type tongues (Fig. 2f) . In oral mucosa of K5.Smad7 mice, the amounts of both total and activated Rac1 were substantially higher (fourfold and eightfold, respectively) compared to those in oral mucosa of wild-type mice ( Fig. 2f) . To determine the functional importance of Smad7-induced Rac1 activation, we knocked down Rac1 in primary keratinocytes isolated from the neonatal skin of wild-type and Smad7 transgenic mice and assayed for cell proliferation and migration. Rac1 knockdown resulted in modestly lower proliferation in keratinocytes from wild-type and Smad7 transgenic mice (Supplementary Fig. 3a-c ) but almost completely abrogated Smad7-induced migration ( Fig. 2g and Supplementary Fig. 3d ), suggesting that higher amounts of Rac1 contributes to Smad7-mediated cell migration. We found that higher Rac1 mRNA levels in keratinocytes from Smad7 transgenic mice correlated with the amounts of total and active Rac1 protein (Fig. 3a,b and Supplementary Fig. 4a,b ), suggesting that a greater amount of Rac1 activation in keratinocytes from Smad7 transgenic mice is, at least in part, a consequence of more Rac1 transcripts. Further, the amount of Rac1 protein increased by approximately threefold ( Fig. 3c ) after knockdown of individual Smad proteins in NOK-SI cells (Supplementary Fig. 4c-e ). These data suggest that normal Smad signaling represses Rac1 transcription. Among the two putative Smad binding elements (SBEs) in the mouse Rac1 promoter (−2.1 kb and −1.5 kb upstream of the coding sequence, referred to here as the SBE-2.1 kb and SBE-1.5 kb sites, respectively), which are in similar regions of the human Rac1 promoter, chromatin immunoprecipitation (ChIP) identified Smad2, Smad3, Smad4 and Smad7 binding to the −1.5 kb site ( Fig. 3d) but not the −2.1 kb site (data not shown) in keratinocytes from wild-type mice; binding of Smad2, Smad3 and Smad4 was significantly lower in keratinocytes from Smad7 transgenic mice ( Fig. 3d) .
Luciferase reporter assays using a SBE-containing Rac1 luciferase (Rac1-Luc) construct showed that knockdown of Smad7 in keratinocytes from wild-type mice led to significantly lower luciferase activity than keratinocytes transfected with scrambled siRNA (Fig. 3e) . Conversely, keratinocytes from Smad7 transgenic mice had higher luciferase activity compared to keratinocytes from wild-type mice, and mutating the SBE attenuated this effect ( Fig. 3f) . Thus, Smad7 binding to the SBE seems to be necessary to expel signaling Smad proteins to abrogate Rac1 repression.
Among known Smad transcriptional co-repressors [29] [30] [31] , we found that CtBP1 bound to the Rac1 promoter SBE-1.5 kb site in keratinocytes from wild-type mice (Fig. 3g) , and Smad7 transgene expression led to significantly lower CtBP1 binding to the SBE (Fig. 3g,h) . When we knocked down CtBP1 in NOK-SI cells, the amount of Rac1 protein and Rac1-Luc activity were higher compared to keratinocytes transfected with scrambled siRNA (Fig. 4a,b ), suggesting that CtBP1 binding to SBE-1.5 kb represses Rac1 expression. Further, knocking down CtBP1 in NOK-SI cells promoted their migration ( Fig. 4c and Supplementary Fig. 4f ). By examination of CtBP1 protein in radiation-induced oral mucositis, we found that CtBP1 was barely detectable in nonirradiated mouse and human oral mucosa ( Fig. 4d-f) ; however, compared to nonirradiated oral mucosa, the number of CtBP1-positive cells was significantly higher in irradiated oral mucosa of wild-type and K5.Smad7 mice, as well as in oral mucosa from humans with oral mucositis ( Fig. 4d-f ). Additionally, CtBP1 mRNA levels in the oral mucosa from irradiated wild-type mice were significantly increased on day 9 and day 10 after irradiation as compared to day 0 ( Fig. 4g) . CtBP1 mRNA levels in the oral mucosa from irradiated K5.Smad7 mice were similar to those of irradiated wild-type mice at earlier time points but returned to their initial levels by day 10 (Fig. 4g) . These results indicate that Smad7 does not reduce CtBP1 mRNA levels but instead inhibits CtBP1 binding to the Rac1 promoter by repelling the Smad-CtBP1 complex from the SBE binding site; further, more rapid reduction in CtBP1 mRNA levels in the oral mucosa from K5.Smad7 mice could represent a marker of healing.
Tat-Smad7 alleviated radiation-induced oral mucositis
The ability of the Smad7 transgene to block multiple pathological processes of oral mucositis prompted us to explore whether localized Smad7 delivery can be used to prevent and treat oral mucositis. Because Smad7 is a nuclear protein, local Smad7 delivery needs to allow Smad7 to rapidly enter cells before saliva washes off the protein. Thus, we produced a recombinant human Smad7 protein with an N-terminal Tat tag (Tat-Smad7), allowing the proteins to rapidly permeate the cell membrane and enter the nucleus [32] [33] [34] . We added a V5 epitope to the C-terminal end of the Tat-Smad7 protein to track its cell penetration (Supplementary Fig. 5a-d) . We tested Tat-Smad7 bioactivity using its ability to block Smad2 phosphorylation (Supplementary Fig. 5c ). We also produced a Tat-Cre recombinant protein with the same tags as a control (Supplementary Fig. 5e,f) .
For oral mucositis prevention, we topically applied Tat-Smad7 or Tat-Cre (in 50% glycerol in PBS (glycerol/PBS)) to the oral cavity daily starting 24 h before irradiation through day 8 after the initiation of irradiation and then examined the treated tissues on day 9. An additional group received palifermin treatment with a clinical regimen: 6.25 mg per kg body weight intraperitoneally (i.p.) daily for 3 d before irradiation and then daily for 3 d beginning 24 h after the last dose of radiation. Tat-Cre showed no effect compared to vehicle control treatment (Fig. 5a,b) . Tat-Smad7 treatments showed preventive effects on ulcer formation similar to those of palifermin (Fig. 5a) . The dose-dependent effect of Tat-Smad7 was more obvious when used on mice given a 20-Gy (BED = 60) single dose of radiation that induced larger oral ulcers than fractionated radiation ( Supplementary  Fig. 5g ). Microscopically, both palifermin and Tat-Smad7 treatment of oral mucosa prevented open ulceration in the majority of cases (Fig. 5b) . Palifermin-treated mucosa showed more keratinocyte growth but also more damaged keratinocytes (condensed or charcoal-like nuclei, swelled mononucleated or multinucleated cells and shattered nuclear fragments in cornified layers) than Tat-Smad7-treated mucosa (Fig. 5b) . Immunostaining revealed significantly more proliferation in mucosa treated with palifermin than in mucosa treated with Tat-Smad7 (Fig. 5c) . The Tat-Smad7-treated group showed lower numbers of cells positive for apoptosis, leukocyte infiltration, nuclear pSmad2 and NF-κB subunit p50 in oral mucosa compared to the palifermin-treated group (Fig. 5b-g) .
To test whether Tat-Smad7 can be used to treat existing oral mucositis, we exposed mice to fractionated (8 Gy × 3) cranial radiation and applied Tat-Smad7 (topically) or palifermin (6.25 mg per kg body weight i.p.) daily from day 6 after the initiation of radiation (when mucosal damage was obvious) until day 9 and then examined the treated tissues on day 10. Although post-radiation administration of palifermin at earlier time points than in the current protocol reduced oral mucositis in mice 35, 36 , palifermin administration with the current protocol did not accelerate ulcer closure (Fig. 6a ) regardless of its hyperproliferative effect on the entire oral mucosa (Fig. 6b) . This is not surprising, as palifermin is approved to prevent but not treat oral mucositis. Tat-Smad7-treated mucosa had smaller ulcer sizes and less pathological alterations after both fractionated and single-dose radiation (Fig. 6a,b and Supplementary Fig. 6a-g) . Outside the zone of ulceration, Tat-Smad7-treated oral mucosa showed less hyperplasia and more differentiated epithelia than palifermintreated oral mucosa (Fig. 6b) . With a 20-Gy single dose of radiation that caused slower healing than fractionated radiation, the effect of Tat-Smad7 on recovery after wound closure was more obvious. In the time frame when a vehicle-treated ulcer was just re-epithelialized, Tat-Smad7-treated mucosa had almost recovered to their normal morphology (Fig. 6c) .
Consistent with observations in K5.Smad7 mice, Tat-Smad7 treatment caused higher Rac1 promoter activity and lower CtBP1 binding to the SBE of the mouse Rac1 promoter compared to PBS treatment (Supplementary Fig. 6h,i) . Tat-Smad7 treatment also resulted in a higher amount of Rac1 protein in the oral mucosa of mice with oral mucositis and in human oral keratinocytes compared to vehicle-treated controls (Fig. 6d,e) . Tat-Smad7-treated human oral keratinocytes after wound scratch had accelerated wound closure compared to vehicletreated human oral keratinocytes ( Fig. 6f and Supplementary Fig. 7a ). Further, irradiated human oral keratinocytes had higher numbers of a r t i c l e s cells positive for nuclear pSmad2 and NF-κB subunit p50 staining than nonirradiated keratinocytes. Radiation-induced pSmad2 and p50 were attenuated by Tat-Smad7 treatment (Supplementary Fig. 7b) .
In contrast, although Tat-Smad7 penetrated oral cancer cells efficiently (Supplementary Fig. 7c) , it did not further elevate the amount of Rac1 protein, which is already abundant in cancer cells (Supplementary Fig. 7d ). This result could account for the faster migration of cancer cells than normal keratinocytes ( Fig. 6f and Supplementary Fig. 7a,e-h ) and the lack of effects of Tat-Smad7 on the promotion of migration in two oral cancer cell lines, MSK921, which does not contain genetic loss of TGF-β signaling components 37 , and Cal27, which has mutated Smad4 (ref. 38) ( Supplementary  Fig. 7e-h) . Colony assays showed that slightly more human oral keratinocytes survived after Tat-Smad7 treatment with or without radiation (Fig. 6g) . Consistent with the notion that fewer cancer cells would survive than normal cells after radiation, squamous cell carcinoma (SCC) cells showed substantial reductions in cell survival after radiation. Treatment with Tat-Smad7 did not affect survival in SCC cells with or without radiation (Fig. 6g) .
DISCUSSION
It is crucial that oral mucositis prevention and treatment overcome epithelial ablation due to massive apoptosis and blunted keratinocyte proliferation. Because palifermin is a mitogen, it has stronger proliferative effects than Smad7. Conversely, the antiapoptotic effect of Smad7 is more potent than that of palifermin. The proliferative and antiapoptotic effects of Smad7 are more obvious in oral mucositis than normal oral mucosa, when TGF-β1, a potent growth inhibitor and apoptosis inducer for epithelial cells 39, 40 , is induced in mucositis. Additionally, our data suggest that greater Rac1 activation is largely responsible for Smad7-mediated keratinocyte migration in wound closure. This finding was initially unexpected, given the documented role of TGF-β signaling in Rho and/or Rac activation in cancer cells through a Smad-independent mechanism 41 . Our study suggests that during oral mucositis, Smad-dependent Rac1 repression could overcome Smad-independent Rac1 activation (if any is present) as a result of greater Smad signaling (evidenced by more pSmad2) and greater amounts of the Smad transcriptional co-repressor CtBP1. When this repression is abrogated by Smad7, it permits Rac1 activationmediated keratinocyte migration. However, in oral cancer cells, signaling Smad proteins are lost or inactivated, or other mechanisms independently activate Rac1; hence, Smad7-mediated abrogation of Rac1 repression would no longer occur. Although Rac1 activation also contributed to keratinocyte proliferation, knocking down Rac1 only partially attenuated the proliferative effect of Smad7. Therefore, the contribution of Rac1 to proliferation seems to be limited, and blocking TGF-β1-induced growth arrest is also needed to overcome radiation-induced growth inhibitory effects.
Dampening excessive inflammation creates a microenvironment for oral mucositis healing [13] [14] [15] [16] . The antagonistic effect of Smad7 on both TGF-β and NF-κB signaling 18 could make Smad7 a more efficient anti-inflammatory molecule than other agents targeting only NF-κB. Because inflammatory cells produce cytokines that further activate TGF-β and NF-κB, less activation of TGF-β and NF-κB signaling, found in oral mucosa from K5.Smad7 mice or Tat-Smad7-treated oral mucosa after radiation, reflects the direct antagonistic effect of Smad7 on these two pathways and the consequence of lower amounts of inflammatory cytokines from infiltrated leukocytes. However, Smad7 did not reduce NF-κB or TGF-β signaling to below their normal physiological conditions. This incomplete blockade of NF-κB or TGF-β npg signaling may be beneficial to oral mucositis healing, as a complete loss of either pathway could induce excessive inflammation 21, 22, 42 .
The primary obstacle to using growth factors to treat oral mucositis in patients with cancer is the potential risk of promoting cancer cell growth 1, 8, 43 . The majority of human oral cancers lose TGF-β signaling in tumor epithelial cells 44, 45 ; thus, anti-Smad-associated cell proliferation and migration by Smad7 would not be effective in cancer cells. In tumors with intact TGF-β signaling, activation of other oncogenic pathways could override TGF-β-induced tumor-suppressive effects. These two scenarios could explain why we did not observe that Smad7 led to greater proliferation and migration in oral cancer cells with mutant or intact TGF-β signaling components. Additionally, TGF-β signaling promotes tumor invasion through mainly Smadindependent mechanisms after loss of TGF-β-induced tumor suppression. Thus, blocking TGF-β signaling by Smad7 in cancer cells could abrogate TGF-β-mediated tumor promotion effects, acting similarly to TGF-β inhibitors currently being used in clinical trials for advanced cancers 46 . Further, the potent anti-inflammatory effect of Smad7 may reduce the risk of tumor progression. Therefore, the long-term effects of Smad7 application on cancer need to be evaluated in vivo. We have not observed spontaneous tumor formation in K5.Smad7 mice 19 . Because Smad7 is not a secreted protein, local and short-term Smad7 protein delivery in oral mucositis treatment should have few systemic effects. Of note, several cell-permeable proteins have moved from molecular mechanism studies into clinical trials 47 . In patients receiving bone-marrow transplant, whose oral epithelia do not contain cancer cells, topical application of Smad7 may be suitable for both the prevention and treatment of oral mucositis. For patients with oral cancer, future studies should assess whether Smad7 application compromises radiotherapy-mediated killing of oral cancer cells.
We describe a mouse model that is resistant to oral mucositis and suggests molecular targets for oral mucositis prevention and treatment. We provide evidence that Smad7-mediated oral mucositis healing is a result of targeting multiple pathogenic processes that are mediated by these molecules (Supplementary Fig. 8) . Our data will instigate future studies to determine the functional contributions of these molecular targets (for example, TGF-β, NF-κB, CtBP1 and Rac1) to oral mucositis pathogenesis and whether they can be used as predictive and therapeutic responsive markers of oral mucositis in patients.
METhODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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This work was supported by NIH grants AR061792 and DE015953 to X.-J.W., R01CA115468 to Q.Z. and R03DA033982 to R.Z. and Q.Z. and the Colorado State cell migration daily. We performed migration assays when cells reached confluency after 24-36 h of siRNA transfection and used Image-J software to document cell migration as the wound area became occupied with migrating cells. For Tat-Smad7 treatment, we exposed cells to Tat-Smad7 protein at 1 µg ml −1 or vehicle control (PBS) in medium after the wound scratch and changed the medium every other day with freshly added Tat-Smad7 until migrating cells fully covered the scratched wound.
Cell survival assay. We performed cell survival assays as previously described 53 with slight modifications. Briefly, we plated cells in 12-well plates at 500 cells per well for nonirradiated wells and increased this number up to 1,500 cells per well with increased radiation doses. We irradiated cells 24 h after they were plated. We added Tat-Smad7 at 1 µg ml −1 or the same volume of PBS used to dissolve Tat-Smad7 (control) to the culture medium of irradiated and nonirradiated cells. We changed the medium every other day with freshly added Tat-Smad7 or PBS for 10-14 d. We fixed colonies in methanol, stained them in 0.5% crystal violet solution (containing 25% methanol) and counted and averaged them from four wells in each experiment. We performed two to three separate experiments for each cell line. We calculated the relative surviving fraction as previously described 53 : the absolute surviving fraction (colony numbers per total plated cells) under each radiation dose divided by the absolute surviving fraction of nonirradiated cells.
